Abstract
Aim:
Iron dyshomeostasis is one of the primary causes of neuronal death in Alzheimer's disease (AD). Huperzine A (HupA), a natural inhibitor of acetylcholinesterase (AChE), is a licensed anti-AD drug in China and a nutraceutical in the United Sates. Here, we investigated the protective effects of HupA against iron overload-induced injury in neurons.
Methods:
Rat cortical neurons were treated with ferric ammonium citrate (FAC), and cell viability was assessed with MTT assays. Reactive oxygen species (ROS) assays and adenosine triphosphate (ATP) assays were performed to assess mitochondrial function. The labile iron pool (LIP) level, cytosolic-aconitase (c-aconitase) activity and iron uptake protein expression were measured to determine iron metabolism changes. The modified Ellman's method was used to evaluate AChE activity.
Results:
HupA significantly attenuated the iron overload-induced decrease in neuronal cell viability. This neuroprotective effect of HupA occurred concurrently with a decrease in ROS and an increase in ATP. Moreover, HupA treatment significantly blocked the upregulation of the LIP level and other aberrant iron metabolism changes induced by iron overload. Additionally, another specific AChE inhibitor, donepezil (Don), at a concentration that caused AChE inhibition equivalent to that of HupA negatively, influenced the aberrant changes in ROS, ATP or LIP that were induced by excessive iron.
Conclusion:
We provide the first demonstration of the protective effects of HupA against iron overload-induced neuronal damage. This beneficial role of HupA may be attributed to its attenuation of oxidative stress and mitochondrial dysfunction and elevation of LIP, and these effects are not associated with its AChE-inhibiting effect.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E . Alzheimer's disease. Lancet 2011; 377: 1019–31.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP . The global prevalence of dementia: A systematic review and metaanalysis. Alzheimers Dement 2013; 9: 63–75. e2.
Citron M . Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 2010; 9: 387–98.
Salvador GA, Uranga RM, Giusto NM . Iron and mechanisms of neurotoxicity. Int J Alzheimers Dis 2010; 2011: 1548–90.
Ke Y, Qian ZM . Iron misregulation in the brain: a primary cause of neurodegenerative disorders. Lancet Neurol 2003; 2: 246–53.
Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L . The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol 2014; 13: 1045–60.
Bilgic B, Pfefferbaum A, Rohlfing T, Sullivan EV, Adalsteinsson E . MRI estimates of brain iron concentration in normal aging using quantitative susceptibility mapping. Neuroimage 2012; 59: 2625–35.
Hagemeier J, Geurts JJ, Zivadinov R . Brain iron accumulation in aging and neurodegenerative disorders. Expert Rev Neurother 2012; 12: 1467–80.
Huang XT, Qian ZM, He X, Gong Q, Wu KC, Jiang LR, et al. Reducing iron in the brain: a novel pharmacologic mechanism of huperzine A in the treatment of Alzheimer's disease. Neurobiol Aging 2014; 35: 1045–54.
Cui ZW, Xie ZX, Wang BF, Zhong ZH, Chen XY, Sun YH, et al. Carvacrol protects neuroblastoma SH-SY5Y cells against Fe2+-induced apoptosis by suppressing activation of MAPK/JNK-NF-kappaB signaling pathway. Acta Pharmacol Sin 2015; 36: 1426–36.
Bostanci MO, Bagirici F . Neuroprotective effect of aminoguanidine on iron-induced neurotoxicity. Brain Res Bull 2008; 76: 57–62.
Bostanci MO, Bas O, Bagirici F . Alpha-tocopherol decreases iron-induced hippocampal and nigral neuron loss. Cell Mol Neurobiol 2010; 30: 389–94.
Dixon SJ, Stockwell BR . The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10: 9–17.
Mena NP, Urrutia PJ, Lourido F, Carrasco CM, Nunez MT . Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders. Mitochondrion 2015; 21: 92–105.
Weinreb O, Mandel S, Bar-Am O, Amit T . Iron-chelating backbone coupled with monoamine oxidase inhibitory moiety as novel pluripotential therapeutic agents for Alzheimer's disease: a tribute to Moussa Youdim. J Neural Transm (Vienna) 2011; 118: 479–92.
Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60: 1685–91.
Bush AI . Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 2002; 23: 1031–8.
Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 1991; 337: 1304–8.
Zhang HY, Zheng CY, Yan H, Wang ZF, Tang LL, Gao X, et al. Potential therapeutic targets of huperzine A for Alzheimer's disease and vascular dementia. Chem Biol Interact 2008; 175: 396–402.
Little JT, Walsh S, Aisen PS . An update on huperzine A as a treatment for Alzheimer's disease. Expert Opin Inv Drug 2008; 17: 209–15.
Wang R, Yan H, Tang XC . Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1–26.
Pohanka M, Hrabinova M, Zemek F, Drtinova L, Bandouchova H, Pikula J . Huperzine induces alteration in oxidative balance and antioxidants in a guinea pig model. Neuro Endocrinol Lett 2011; 32: 95–100.
Xiao XQ, Wang R, Tang XC . Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J Neurosci Res 2000; 61: 564–9.
Xiao XQ, Zhang HY, Tang XC . Huperzine A attenuates amyloid beta-peptide fragment 25–35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 2002; 67: 30–6.
Xiao XQ, Yang JW, Tang XC . Huperzine A protects rat pheochromocytoma cells against hydrogen peroxide-induced injury. Neurosci Lett 1999; 275: 73–6.
Mao XY, Zhou HH, Li X, Liu ZQ . Huperzine A alleviates oxidative glutamate toxicity in hippocampal HT22 cells via activating BDNF/TrkB-dependent PI3K/Akt/mTOR signaling pathway. Cell Mol Neurobiol 2016; 36: 915–25.
Wang LM, Han YF, Tang XC . Huperzine A improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Eur J Pharmacol 2000; 398: 65–72.
Shang YZ, Ye JW, Tang XC . Improving effects of huperzine A on abnormal lipid peroxidation and superoxide dismutase in aged rats. Acta Pharmacol Sin 1999; 20: 824–8.
Yang L, Ye CY, Huang XT, Tang XC, Zhang HY . Decreased accumulation of subcellular amyloid-beta with improved mitochondrial function mediates the neuroprotective effect of huperzine A. J Alzheimers Dis 2012; 31: 131–42.
Lu H, Jiang M, Lu L, Zheng G, Dong Q . Ultrastructural mitochondria changes in perihematomal brain and neuroprotective effects of Huperzine A after acute intracerebral hemorrhage. Neuropsychiatr Dis Treat 2015; 11: 2649–57.
Wu J, Hua Y, Keep RF, Nakamura T, Hoff JT, Xi G . Iron and iron-handling proteins in the brain after intracerebral hemorrhage. Stroke 2003; 34: 2964–9.
Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, et al. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 2004; 6: 165–9.
Ho KP, Li L, Zhao L, Qian ZM . Genistein protects primary cortical neurons from iron-induced lipid peroxidation. Mol Cell Biochem 2003; 247: 219–22.
Epsztejn S, Kakhlon O, Glickstein H, Breuer W, Cabantchik I . Fluorescence analysis of the labile iron pool of mammalian cells. Anal Biochem 1997; 248: 31–40.
Gonzalez D, Drapier JC, Bouton C . Endogenous nitration of iron regulatory protein-1 (IRP-1) in nitric oxide-producing murine macrophages: further insight into the mechanism of nitration in vivo and its impact on IRP-1 functions. J Biol Chem 2004; 279: 43345–51.
Ellman GL, Courtney KD . Andres V Jr, Feather-Stone RM . A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–9.
Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, et al. Iron: the Redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 2007; 32: 1640–5.
Lei Y, Yang L, Ye CY, Qin MY, Yang HY, Jiang HL, et al. Involvement of intracellular and mitochondrial abeta in the ameliorative effects of Huperzine A against oligomeric abeta42-induced injury in primary rat Neurons. PLoS One 2015; 10: e0128366.
Wang R, Xiao XQ, Tang XC . Huperzine A attenuates hydrogen peroxide-induced apoptosis by regulating expression of apoptosis-related genes in rat PC12 cells. Neuroreport 2001; 12: 2629–34.
Silvestri L, Camaschella C . A potential pathogenetic role of iron in Alzheimer's disease. J Cell Mol Med 2008; 12: 1548–50.
Bishop GM, Robinson SR . Quantitative analysis of cell death and ferritin expression in response to cortical iron: implications for hypoxia-ischemia and stroke. Brain Res 2001; 907: 175–87.
Hayter CL, Bishop GM, Robinson SR . Pharmacological but not physiological concentrations of melatonin reduce iron-induced neuronal death in rat cerebral cortex. Neurosci Lett 2004; 362: 182–4.
Salvador GA, Oteiza PI . Iron overload triggers redox-sensitive signals in human IMR-32 neuroblastoma cells. Neurotoxicology 2011; 32: 75–82.
Dixon SJ, Stockwell BR . The role of iron and reactive oxygen species in cell death. Nat Chem Biol 2014; 10: 9–17.
He Q, Song N, Xu HM, Wang R, Xie JX, Jiang H . Alpha-synuclein aggregation is involved in the toxicity induced by ferric iron to SK-N-SH neuroblastoma cells. J Neural Transm (Vienna) 2011; 118: 397–406.
Xiao XQ, Wang R, Tang XC . Huperzine A and tacrine attenuate beta-amyloid peptide-induced oxidative injury. J Neurosci Res 2000; 61: 564–9.
Pelizzoni I, Macco R, Morini MF, Zacchetti D, Grohovaz F, Codazzi F . Iron handling in hippocampal neurons: activity-dependent iron entry and mitochondria-mediated neurotoxicity. Aging Cell 2011; 10: 172–83.
Sripetchwandee J, Sanit J, Chattipakorn N, Chattipakorn SC . Mitochondrial calcium uniporter blocker effectively prevents brain mitochondrial dysfunction caused by iron overload. Life Sci 2013; 92: 298–304.
Urrutia PJ, Mena NP, Nunez MT . The interplay between iron accumulation, mitochondrial dysfunction, and inflammation during the execution step of neurodegenerative disorders. Front Pharmacol 2014; 5: 38.
Pardo Andreu GL, Inada NM, Vercesi AE, Curti C . Uncoupling and oxidative stress in liver mitochondria isolated from rats with acute iron overload. Arch Toxicol 2009; 83: 47–53.
Gao X, Campian JL, Qian M, Sun XF, Eaton JW . Mitochondrial DNA damage in iron overload. J Biol Chem 2009; 284: 4767–75.
Park J, Lee DG, Kim B, Park SJ, Kim JH, Lee SR, et al. Iron overload triggers mitochondrial fragmentation via calcineurin-sensitive signals in HT-22 hippocampal neuron cells. Toxicology 2015; 337: 39–46.
Carafoli E, Lehninger AL . Binding of adenine nucleotides by mitochondria during active uptake of CA++. Biochem Biophys Res Commun 1964; 16: 66–70.
Hirsch T, Marchetti P, Susin SA, Dallaporta B, Zamzami N, Marzo I, et al. The apoptosis-necrosis paradox. Apoptogenic proteases activated after mitochondrial permeability transition determine the mode of cell death. Oncogene 1997; 15: 1573–81.
Beal MF . Mitochondria take center stage in aging and neurodegeneration. Ann Neurol 2005; 58: 495–505.
Gruber J, Fong S, Chen CB, Yoong S, Pastorin G, Schaffer S, et al. Mitochondria-targeted antioxidants and metabolic modulators as pharmacological interventions to slow ageing. Biotechnol Adv 2013; 31: 563–92.
Shadel GS, Horvath TL . Mitochondrial ROS signaling in organismal homeostasis. Cell 2015; 163: 560–9.
Staubli A, Boelsterli UA . The labile iron pool in hepatocytes: prooxidant-induced increase in free iron precedes oxidative cell injury. Am J Physiol 1998; 274: G1031–7.
Li Y, Deng Y, Tang Y, Yu H, Gao C, Liu L, et al. Quercetin protects rat hepatocytes from oxidative damage induced by ethanol and iron by maintaining intercellular liable iron pool. Hum Exp Toxicol 2014; 33: 534–41.
Kakhlon O, Cabantchik ZI . The labile iron pool: characterization, measurement, and participation in cellular processes. Free Radic Biol Med 2002; 33: 1037–46.
Kruszewski M . Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 2003; 531: 81–92.
Ke Y, Qian ZM . Brain iron metabolism: neurobiology and neurochemistry. Prog Neurobiol 2007; 83: 149–73.
Roy CN, Blemings KP, Deck KM, Davies PS, Anderson EL, Eisenstein RS, et al. Increased IRP1 and IRP2 RNA binding activity accompanies a reduction of the labile iron pool in HFE-expressing cells. J Cell Physiol 2002; 190: 218–26.
Ho KP, Xiao DS, Ke Y, Qian ZM . Exercise decreases cytosolic aconitase activity in the liver, spleen, and bone marrow in rats. Biochem Biophys Res Commun 2001; 282: 264–7.
Eisenstein RS . Iron regulatory proteins and the molecular control of mammalian iron metabolism. Annu Rev Nutr 2000; 20: 627–62.
Rouault TA . The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol 2006; 2: 406–14.
Brissot P, Ropert M, Le Lan C, Loreal O . Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta 2012; 1820: 403–10.
Acknowledgements
The authors are grateful to the National Natural Science Foundation of China (No 81522045 and 31400932).
Author information
Authors and Affiliations
Corresponding author
PowerPoint slides
Rights and permissions
About this article
Cite this article
Tao, Lx., Huang, Xt., Chen, Yt. et al. Acetylcholinesterase-independent protective effects of huperzine A against iron overload-induced oxidative damage and aberrant iron metabolism signaling in rat cortical neurons. Acta Pharmacol Sin 37, 1391–1400 (2016). https://doi.org/10.1038/aps.2016.78
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2016.78
Keywords
This article is cited by
-
A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies–Emphasis on Alzheimer’s Disease Pathogenesis
Neurochemical Research (2022)
-
An optically active isochroman-2H-chromene conjugate potently suppresses neuronal oxidative injuries associated with the PI3K/Akt and MAPK signaling pathways
Acta Pharmacologica Sinica (2021)
-
Huperzine A ameliorates obesity-related cognitive performance impairments involving neuronal insulin signaling pathway in mice
Acta Pharmacologica Sinica (2020)
-
Iron dysregulates APP processing accompanying with sAPPα cellular retention and β-secretase inhibition in rat cortical neurons
Acta Pharmacologica Sinica (2018)
